Doc description: Information Disclosure Statement (IDS) Filed
Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10599692
Filing Date		2006-10-05
First Named Inventor	Predi	man K. Shah
Art Unit		1633
Examiner Name	Janet	L. Epps Smith
Attorney Docket Numb	ner .	67789-101US0

			PATENTS	Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6506799		2003-01-14	Dasseux et al.	
	2	6773719		2004-08-10	Rodriquez et al.	
	3	7435717		2008-10-14	Bisgaier et al.	
	4	5876968		1999-03-02	Sintori et al.	
	5	4868116		1989-09-19	Morgan et al.	
	6	4980286		1990-12-25	Morgan et al.	
	7	5721114		1998-02-24	Abramansen et al.	
	8	5834596		1998-11-10	Ageland et al.	

9	5990081	1999-11-23	Ageland et al.	
10	6004925	1999-12-21	Dasseux et al.	
11	6037323	2000-03-14	Dasseux et al.	
12	6046166	2000-04-04	Dasseux et al.	
13	6090921	2000-07-18	Winge et al.	
14	6107467	2000-08-22	Ageland et al.	
15	6258596	2001-07-10	Benoit et al.	
16	6265377	2001-07-24	Dasseux et al.	
17	6329341	2001-12-11	Dasseux et al.	
18	6376464	2002-04-23	Dasseux et al.	
19	6423830	2002-07-23	Winge et al.	

20	6506879	2003-01-14	Ageland et al.	
21	6559284	2003-05-06	Ageland et ai.	
22	6617134	2003-09-09	Sirtori et al.	
23	6080422	2000-06-27	Williams	
24	4970144	1990-11-13	Fareed et a.	
25	5827516	1998-10-27	Urban et al.	
26	5861276	1999-01-19	Kwak Ju-Won et al.	
27	5972890	2002-03-13	Lees et al.	
28	6635623	2003-10-21	Hoogeveen et al.	
29	6727102	2004-04-27	Holvoet et al.	
30	5643757	1997-07-01	Malik et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

If you wish to add additional U.S. Patent citation information please click the Add button.

Application Number		10599692
Filing Date		2006-10-05
First Named Inventor Predir		man K. Shah
Art Unit		1633
Examiner Name	Janet	L. Epps Smith

Add

				U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
		Publication Number				of cited Document		ages,Columns,Lines where elevant Passages or Relevant gures Appear			
	1		20020156007	A1	2002-10	1-24	Graversen et a	al.			
If you wisi	h to a	dd a	dditional U.S. Publi						d butto		
					FOREIG	GN PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No		reign Document mber ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	wc	2003-026492	wo			2003-01-30	Hubbell et al.			
	2	wc	2005-097206	wo			2005-10-20	Bisgaier, Charles L			
	3	wc	2002-080954	wo			2002-10-17	Nilsson et al.			
	4	wc	2002-42426	wo			2002-05-30	Lei et al.			
	5	wc) 2002-48388 A2	wo			2002-06-20	Agnello, Vincent			Е
	6	wc	2003-007689	wo			2003-01-30	Hubbell et al.			

	Application Number		10599692	
	Filing Date		2006-10-05	
INFORMATION DISCLOSURE	First Named Inventor Predim		man K. Shah	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1633	
(Not for Submission under 37 GFR 1.33)	Examiner Name	Janet	L. Epps Smith	
	Attorney Docket Numb	er	67789-101US0	

7	0267703	E₽	1991-06-19	Erba Farmitalia	
8	0469017	EP	1994-06-15	Sirtori	
9	96/37608	wo	1996-11-28	Rhone-Poulenc Rorer, S. A.	
10	0494848	EP	1997-03-26	Pharmacia AB	
11	02/30359	wo	2002-04-18	University of Cincinnati	
12	93/12143	wo	1993-06-24	Kabi Pharmacia AB	
13	89/07136	wo	1989-08-10	Whitehead Institute for Biomedical Research	
14	90/02806	wo	1990-03-22	Whitehead Institute for Biomedical Research	
15	95/23592	wo	1995-09-08	University of British Columbia	
16	90/12879	wo	1990-11-01	Sirtoli et al.	
17	EP 0 911 344 A1	EP	1999-04-28	Uchida et al.	

	Application Number		10599692
	Filing Date		2006-10-05
INFORMATION DISCLOSURE	First Named Inventor	Predi	man K. Shah
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1633
(Not for Submission under 37 GFR 1.33)	Examiner Name	Janet	L. Epps Smith
	Attorney Docket Numb	er	67789-101US0

18	EP 1 186 299 A1	E₽	2002-03-13	Cabezas et al.	
19	EP 1 394 177 A1	EP	2004-03-03	Niimi et al.	
20	WO 1993-18067 A1	wo	1993-09-16	Kundu et al.	
21	WO 1994-00592	wo	1994-01-06	Cohen, Margo P.	
22	WO 1997-43311	wo	1997-11-20	Bruckdorfer et al.	
23	WO 1998-13385	wo	1998-04-02	Hallbert et al.	
24	WO 1998-42751	wo	1998-10-01	Lunec et al.	
25	WO 1998-56938	wo	1998-12-17	Guevara et al.	
26	WO 1999-08109	wo	1998-02-18	Witztum et al.	
27	WO 1999-18986 A	wo	1999-04-22	Goldberg et al.	
28	WO 1999-46598	wo	1999-09-16	Innerarity et al.	

	29	WO 2000-02920 A1	wo		2000-01-20	McCormick, Sally Priscilla Anna		
	30	WO 2001-32070 A2	wo		2001-05-10	Witzum et al.		
	31	WO 2001-57274 A2	wo		2001-08-09	Penn et al.		
	32	WO 2001-64008 A2	wo		2001-09-07	Fruchart et al.		
	33	WO 2001-68119	wo		2001-09-20	Hansson et al.		
	34	WO 2002-06314 A2	wo		2002-01-24	Narvanen et al.		
If you wis	h to a	dd additional Foreign P				lease click the Add butto		
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when approp date, pages(s), volume-is		T6
	1	International Search Re	port dated July 3, 2	2003 for	PCT/US02/310	68 (DWT ref. 67789-051W0	00), 2 pages.	
	2	International Preliminary	Examination Rep	ort date	d 06/28/2004 for	PCT/US02/31068 (DWTre	f. 67789-051WO0), 3	

Search Report for dated 08/23/2005 European patent application no. 02799686.7 (DWT ref. 67789-051EP0), 3 pages.

4	Examination Report dated 01/08/2010 European patent application no. 02799686.7 (DWT ref: 67789-051EP0), 4 pages.	
5	International PCT Search Report and Writtlen Opinion dated December 29, 2005 for PCT/US05/11466 (DWT ref. no. 67789-101W00), 7 pages.	
6	International Preliminary Report on Palentability dated October 11, 2006 for PCT/US05/11466 (DWT ref. no. 67789-101W00, 4 pages.	
7	Examination Report dated 08/21/2007 for European patent application no. 05763769.6 (DWT ref. no. 67789-101EP0), 4 pages.	
8	Examination Report dated 06/25/2008 for European patent application no. 05763789.6 (DWT ref. no. 67789-101EPD), 7 pages.	
9	Examination Report dated July 23, 2009 for Japanese patient application no. 2007-507425 (DWT ref. no. 67789-101JPD), 5 pages.	
10	Non-final Office Action dated January 25, 2005 for U.S. 10/260,094 (DWT Ref. No. 67789-051US0).	
11	Non-final Office Action dated June 17, 2005 for U.S. 10/260,094 (DWT Ref. No. 67769-051US0).	
12	Final Office Action dated December 15, 2005 for U.S. 10/250,094 (DWT Ref. No. 67789-051US0).	
13	Non-final Office Action dated October 10, 2006 for U.S. 10/260,094 (DWT Ref. No. 67789-051US0).	
14	Non-final Office Action dated April 24, 2007 for U.S. 10/260,094 (DWT Ref. No. 67789-051US0).	

| Application Number | 10599922 | Fing Date | 2008-10-45 | Fing Date |

15	Non-final Office Action dated September 20, 2007 for U.S. 10/260,094 (DWT Ref. No. 67789-051US0).	
16	Final Office Action dated May 2, 2008 for U.S. 10/260,094 (DWT Ref. No. 67789-051US0).	
17	Non-final Office Action dated November 4, 2008 for U.S. 10/260,094 (DWT Ref. No. 67789-051US0).	
18	Non-final Office Action dated September 30, 2009 for U.S. 10/260,094 (DWT Ref. No. 67789-051US0).	
19	Final Office Action dated July 8, 2010 for U.S. 10/260,094 (DWT Ref. No. 67789-051US0).	
20	Interview Summary dated August 12, 2010 for U.S. 10/280,094 (DWT Ref. No. 67789-051US0).	
21	Non-final Office Action dated October 6, 2010 for U.S. 10/250,094 (DWT Ref. No. 67789-051US0).	
22	Final Office Action dated April 21, 2011 for U.S. 10/260,894 (DWT Ref. No. 67789-051US0).	
23	European Search Report dated April 4, 2007 for European patent application no. 05763769 6 (DWT ref. no 67789-101EPD), 4 pages.	
24	SHAH et al., Transplanation of bone maintow cells transduced with adeno-associated virus vectors encoding the apo A-1 millano gene inhibits atherosclerosis in apo E-null mice., Circulation, Vol. 110, no. 17S, October 26, 2004, pages 330-331.	
25	SHAH et al., A Single inframuscular rejection of recombinant adeno-associated virus vectors encoding the app A-1 millano gene inhibits atherosclerosis in app E-null miles., Orculation, Vol. 110, no. 178, October 26, 2004, pages 330	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10599692
Ì	Filing Date		2006-10-05
	First Named Inventor	Predi	man K. Shah
	Art Unit		1633
	Examiner Name Janet		L. Epps Smith
	Attorney Docket Numb	er	67789-101US0

26	AVIGAU, M., et al., "Persources active site required for protection against LDL codation movives is free sufflydyl grup and al. efficient from that required for its surjections of personations sufficience studies, selective status of human paraconses allogimes Q and R," (1996), Artonoscier. Thromb. Vasco Biol., 18, pp. 1617-1624.	
27	AVIRAM, M., et al., "Paracocosse inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paracocosse," (1938), J. Clin. Invest., 101, No. 8, pp. 1581-1590.	
28	BILLECKE, S., et a., "Human serum paracutonase (PONI) isozymes Q and R hydrolyze lactones and cyclic carbonate esters," (2000). Drug Metab. Dispos. 28, pp. 1335-1342.	
29	CALABRESI, L., et al., "Increased postprancial lipernia in Apo A-Millano carriers," (1993), Arterioscier, and Thromb., 13(4), pp. 521-528.	
30	CHIESA, G., et al., "Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-tmillano" (1998), Athersol., 136, pp. 139-146.	
31	DRAGONOV, D.I., et al., "Rabbit serum paraoxonase 3 (PCN3) is a high density ipoprotein-associated lactonase and protects low density ipoprotein against oxidation" (2000), J. Biol. Chem. 275(43), pp. 33435-33442.	
32	FRANCESCHINI, G., et al., "Apolipoproten A-Imiliano: disulfide-linked dimers norease high density lipoproten stability and hinder particle interconversion in carrier plasma," (1990), J. Bio. Chem., 265(21), pp. 12224-12231.	
33	FRANCESCHINI, G., et at, "Apolipoproten A-limitanc: accelerated binding and dissociation from lipids of a human apolipoproten variant," (1 865), I. Biol. Chem., Vol. 260:30, pp. 16321-16325.	
34	FRANCESCHINI, G., et al., "Increased choissierol efflux potential of sera from apoA-imiliano carriers and transgeno mee," (1999), Arterioscler. Thromb. Vasco Bios., 19, pp 1257-1262.	
35	FRANCESCHINI, G., et al., "Relationship of the phenotypic expression of the A-Imiliano apoprotein with plasma lipid and lipoprotein patterns," (1985), Athersid., 58, pp. 159-174.	
36	FRANCESCHINI, et al. "Apolipoprotein A-Imiliano correlation between high density lipoprotein subclass distribution and triglycentdemia," (1987), Atleniosaleriosis 7-038-435.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10599692
Filing Date		2006-10-05
First Named Inventor	Predir	man K. Shah
Art Unit		1633
Examiner Name	Janet	L. Epps Smith
Attorney Docket Numb	er	67789-101US0

37	FRANCESCHINI, G., et al., Altered lipid binding properties in a human apolipoprotein variant," Recent Aspects of Diagnosis and Treatment of Lipoprotein Disorders: impact on prevention of Atherosclerotic Diseases, Alan R., Liss, Inc., 1988 pp. 73-80.	
38	GUALANDRI, N., et a., "AlfMiano apoprolen identification of the complete kindred and evidence of a dominant genetic transmission," (1995), Am. J. Hum. Genet., 37, pp. 1083-97.	
39	JAMES, R.W., et al., "Modulated serum activities and concentrations of paracoonese in high density incorrotein - deficiency states," (1998), Athersol., 139, pp. 77-82.	
40	KAUL, et al., "Intramural delivery of recombinant apolipoproten A-Imiliano phospholipid complex (ETC-216) milbits (n- Stent Stenosis in porcine coronary arteries", Crouletion 107:2551-2554 (2003).	
41	Ll, D., et al., "Inhibition of arterial thrombus formation by apoAlimiano," (1999), Arterbaciler. Thromb. Vasco Biol., 19, pp.378-383.	
42	NILSSON et al., "Lipoprotein-like phospholipic particles inhibit the smooth muscle cell cylobxicity of ysophosphaticycholine and platelet-activating factor" (1999), Arteroscier. Thromb. Vasco Bio. 18, pp. 13-19.	
43	ROMA, et al., "In vivo metabolism of a mutant form of apolipoproten A-I, APO A-timilanc, associated with familial hyposiphalipoproteinems," The Journal of Clin. Invest., volume 91, April 1993, pp. 1445-1452.	
44	ROSSENEU and LABEUR, "Physiological significance of apolipoprotein mutants," (1995), The FASEB Journal, 9, pp. 768-776.	
45	SHAH, P.K., et al., "Effects of recombinant apolipoprotein A-Imiliano on aortic atherosclerosis in apolipoprotein e- deficient mice" (1998). Circulation 97, pp. 780-785.	
46	SHAH, et al., "High-dose recombinant apolipoprotein A-limitano mobilizes lissue cholesterol and rapidly reduces plaque Lipid and macrophage content in apolipoprotein e-deficient mice, potential implications for acute plaque stabilization," (2001) Circulation 103:3047-3050.	
47	SIRTORI, C.R., et al., "Recombinant apolipoprolens for the treatment of vascular diseases," (1999), Athersci., 142, pp. 29-40.	

	48	SIRTORI, C.R., et al., "Familial disorders of plasma apolipoproteins," (1985), Klin Wochenschrift, 63, pp. 481-489.			
	49	SIRTORI, C.R., et al., "Apolipoprotein Almilano, (The First Molecular Variant of Human Apolipoprotein)," (1962), La Ricera C.Un. Lab., 12, pp. 63-86.			
	50	SOMA, M.R., et al., "Recombinant apolipoproten A-tmilano driner inhibits carolid infilmal thickening induced by pervescular manipulation in Rabbits," (1995), Circulation Res. 76, pp. 405-411.			
If you wish to add additional non-patent literature document citation information please click the Add button Add					
EXAMINER SIGNATURE					

*EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at www.USPTO.000 or NRPP 04104. I Enter office that issued the document, by the No-clear ow (WIPO Standard ST3.) I For Lapranese patent document, the archaest on the year of the region of the Emperor want preceds the sent ancher of the opath of Counter of the Count

Date Considered

Examiner Signature